<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="/rss.css" type="text/css"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/"
    xmlns:cc="http://web.resource.org/cc/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:extra="http://www.w3.org/1999/xhtml"
    xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
    <channel rdf:about="http://www.biomedcentral.com/feeds/latestarticles/journal?journal=bmcgastroenterol&amp;quantity=&amp;format=rss&amp;version=">
        <title>BMC Gastroenterology - Latest Articles</title>
        <link>http://www.biomedcentral.com/bmcgastroenterol/</link>
        <description>The latest research articles published by BMC Gastroenterology</description>
        <dc:date>2009-12-03T00:00:00Z</dc:date>
        <items>
            <rdf:Seq>
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-230X/9/91" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-230X/9/90" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-230X/9/89" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-230X/9/88" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-230X/9/87" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-230X/9/86" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-230X/9/85" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-230X/9/84" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-230X/9/83" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-230X/9/82" />
                            </rdf:Seq>
        </items>
        <extra:info rdf:parseType="Literal">
            <html:div style="font:14px Verdana, Geneva, Arial, Helvetica, sans-serif" xmlns:html="http://www.w3.org/1999/xhtml">
                <html:span style="font-weight:bold">
                    This is an RSS newsfeed from BioMed Central
                </html:span>
                <html:br />
                <html:span style="font-size: 12px;">
                    It is intended to be used with an RSS reader. For more information about RSS newsfeeds from BioMed Central, visit
                    <html:br />
                    <html:a href="http://www.biomedcentral.com/info/about/rss/" style="color:#3333CC; font-size:12px;">
                        http://www.biomedcentral.com/info/about/rss/
                    </html:a>
                    <html:br />
                </html:span>
            </html:div>
        </extra:info>
        <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </channel>
        <item rdf:about="http://www.biomedcentral.com/1471-230X/9/91">
        <title>Sensitivity and specificity of plasma disappearance rate of indocyanine green as a prognostic indicator in acute liver failure</title>
        <description>Background:
In patients presenting with acute liver failure (ALF) prediction of prognosis is vital to determine the need of transplantation. Based on the evidence that plasma disappearance rate of indocyanine green (ICG-PDR) correlates with liver cell function, we evaluated the ability of ICG-PDR measured by pulse dye densitometry to predict outcome in patients with acute liver failure.
Methods:
Prospectively markers of hepatocellular injury, synthesis and excretion, including ICG-PDR were measured daily until liver transplantation, death, discharge from intensive care unit, or up to 7 days in 25 patients with acute liver failure. Receiver operating curve (ROC) analysis was performed to assess the value of ICG-PDR to predict outcome in ALF.
Results:
The 25 patients analyzed included 18 that recovered spontaneously and 7 that underwent liver transplantation (n = 6) or died (n = 1). Causes of ALF included viral hepatitis (n = 4), toxic liver injury (n = 15), ischemic liver injury (n = 2), and cryptogenic liver failure (n = 4). King&apos;s college criteria were fulfilled in 85.7% of patients not recovering spontaneously and in 16.7% of patients recovering spontaneously. The mean ICG-PDR measured on day 1 in patients recovering spontaneously was 12.0 +/- 7.8 %/min and in patients not recovering spontaneously 4.3 +/- 2.0 %/min (P = 0.002). By ROC analysis the sensitivity and specificity of an ICG-PDR value [less than or equal to] 6.3%/min on study day 1 were 85.7% and 88.9%, respectively, for predicting a non spontaneous outcome in ALF.
Conclusions:
ICG-PDR allows early and sensitive bedside assessment of liver dysfunction in ALF. Measurement of ICG-PDR might be helpful in predicting the outcome in acute liver failure.Trial registration: Clinicaltrials.gov, NCT 00245310</description>
        <link>http://www.biomedcentral.com/1471-230X/9/91</link>
                <dc:creator>Uta Merle</dc:creator>
                <dc:creator>Olivia Sieg</dc:creator>
                <dc:creator>Wolfgang Stremmel</dc:creator>
                <dc:creator>Jens Encke</dc:creator>
                <dc:creator>Christoph Eisenbach</dc:creator>
                <dc:source>BMC Gastroenterology 2009, 9:91</dc:source>
        <dc:date>2009-12-03T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-230X-9-91</dc:identifier>
        <prism:publicationName>BMC Gastroenterology</prism:publicationName>
        <prism:issn>1471-230X</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>91</prism:startingPage>
        <prism:publicationDate>2009-12-03T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-230X/9/90">
        <title>Polymorphism in the oxytocin promoter region in patients with lactase non-persistence is not related to symptoms</title>
        <description>Aim: Oxytocin and the oxytocin receptor have been demonstrated in the gastrointestinal (GI) tract and have been shown to exert physiological effects on gut motility. The role for oxytocin in the pathophysiology of GI complaints is unknown. The aim of this study was to examine genetic variations or polymorphism of oxytocin (OXT) and its receptor (OXTR) genes in patients with GI complaints without visible organic abnormalities.MethodGenetic variants in the OXT promoter region, and in the OXTR gene in DNA samples from 131 rigorously evaluated patients with Irritable Bowel Syndrome (IBS),  408 homozygous subjects referred for lactase (LCT-13910 C&gt;T, rs4988235) genotyping, and 299 asymptomatic blood donors were compared. One polymorphism related to the OXT gene (rs6133010 A&gt;G) and 4 related to the OXTR gene (rs1465386 G&gt;T, rs3806675 G&gt;A, rs968389 A&gt;G, rs1042778 G&gt;T) were selected for genotyping using Applied Biosystems 7900 HT allele discrimination assays.
Results:
There were no statistically significant differences in the genotype or allele frequencies in any of the SNPs when IBS patients were compared to healthy controls. Among subjects referred for lactase genotyping, the rs6133010 A&gt;G OXT promoter A/G genotype tended to be more common in the 154 non-persistent (27.3%) subjects than in the 254 lactase persistant (18.1%) subjects and in the healthy controls (19.4%) (p=0.08). When direct comparing, the A/G genotype was less common in the OXT promoter region in controls (p=0.09) and in subjects with lactase persistence (p=0.03) compared to subjects with lactase non-persistence. When healthy controls were viewed according to their own LCT-13910 genotypes, the C/C lactase non-persistent controls had a higher frequency for the OXT promoter A/G genotype than LCT-13910 T/T lactase persistent controls (41.2% vs 13.1%).No significant differences in frequencies of the investigated OXTR SNPs were noted in this study.
Conclusion:
The results suggest that polymorphism in the promoter region of the OXT gene is most common in subjects with lactase non-persistence. This polymorphism may not be related to GI symptoms, as it is related to lactase non-persistence also in healthy controls.</description>
        <link>http://www.biomedcentral.com/1471-230X/9/90</link>
                <dc:creator>Mikael Truedsson</dc:creator>
                <dc:creator>Joyce Carlson</dc:creator>
                <dc:creator>Magnus Simren</dc:creator>
                <dc:creator>Bodil Ohlsson</dc:creator>
                <dc:source>BMC Gastroenterology 2009, 9:90</dc:source>
        <dc:date>2009-11-30T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-230X-9-90</dc:identifier>
        <prism:publicationName>BMC Gastroenterology</prism:publicationName>
        <prism:issn>1471-230X</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>90</prism:startingPage>
        <prism:publicationDate>2009-11-30T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-230X/9/89">
        <title>What are the implications of the spontaneous spleno-renal shunts in liver cirrhosis?</title>
        <description>Background:
Although significant advances are expected to be made in the assessment of the portal hypertension-related complications, the prognostic role of spleno-renal shunts has not been fully explored so far. Clarifying this aspect could help tackle the life-treating events occurring in patients suffering from liver cirrhosis. The aim of the study was to analyze the relationships between the spleno-renal shunts presence at doppler ultrasound and the liver cirrhosis complications.
Methods:
Design: eighty one patients out of 129 formed the study population (35 females). Chronic liver damage in these patients was caused by HCV (66), HBV (2), alcohol abuse (2) or unknown etiology, likely non-alcoholic steatohepatitis (11). Setting: two Liver Units of university/primary hospitals in Southern Italy. Main outcome measures: grading of esofageal varices; detection of ascites: assessment of hepatic encephalopathy; evaluation of liver cirrhosis severity; tracking hepatocellular carcinoma; doppler features of spleno-renal shunts and splenic flow velocity; spleen longitudinal diameter at sonography.
Results:
The prevalence of spleno-renal shunts was 18.5%, without no difference concerning the etiology (HCV versus non-HCV, p = 0.870); the prevalence of hepatocellular carcinoma in patients with spleno-renal shunts was superior to that of patients without them (Pearson Chi-square, p = 0.006, power of sample size 74%), also after adjustment for liver decompensation (p = 0.024). The median score of hepatic encephalopathy in patients with and without spleno-renal shunts was similar, i.e., 0 (range, 0-2) versus 0 (0 - 3), p = 0.67. The median splenic vein flow velocity in patients with spleno-renal shunts was significantly inferior to that of patients without them, i.e., 13 cm/sec (95% confidence intervals, 6-18) versus 21 cm/sec (17-24), p &lt; 0.0001. By far the largest percentage of large esophageal varices was in patients without spleno-renal shunts (p = 0.005). In contrast, the frequency of ascites and hepatic encephalopathy severity was overlapping in the two groups. BMI values but not Child-Pugh&apos;s classification predicted spleno-renal shunts (Ors = 1.84, 95% confidence intervals = 1.28-2.64, p = 0.001 and 1.145, 95% confidence intervals = 0.77-1.51, p = 0.66).
Conclusion:
Taking into consideration the relatively small sample size, patients with spleno-renal shunts are burdened by an increased incidence of hepatocellular carcinoma. BMI predicted the spleno-renal shunts presence.</description>
        <link>http://www.biomedcentral.com/1471-230X/9/89</link>
                <dc:creator>Giovanni Tarantino</dc:creator>
                <dc:creator>Vincenzo Citro</dc:creator>
                <dc:creator>Paolo Conca</dc:creator>
                <dc:creator>Antonio Riccio</dc:creator>
                <dc:creator>Marianna Tarantino</dc:creator>
                <dc:creator>Domenico Capone</dc:creator>
                <dc:creator>Michele Cirillo</dc:creator>
                <dc:creator>Roberto Lobello</dc:creator>
                <dc:creator>Vittorio Iaccarino</dc:creator>
                <dc:source>BMC Gastroenterology 2009, 9:89</dc:source>
        <dc:date>2009-11-24T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-230X-9-89</dc:identifier>
        <prism:publicationName>BMC Gastroenterology</prism:publicationName>
        <prism:issn>1471-230X</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>89</prism:startingPage>
        <prism:publicationDate>2009-11-24T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-230X/9/88">
        <title>Supplementation with vitamin E (alpha-tocopherol) in diabetic rats: effects on the proximal colon</title>
        <description>Background:
Neuropathy is one of the complications caused by diabetes mellitus (DM) which is directly related to the gastrointestinal manifestations of the disease. Antioxidant substances such as vitamin E may have an important role in the reduction of the neurological damages caused by DM. The aim of this study was to evaluate if vitamin E (alpha-tocopherol) in different concentrations perform any effects over the morphology of the intestinal wall and intrinsic innervation in the proximal colon of diabetic rats.
Methods:
Thirty rats (90-day-old) were distributed into the following groups: N: normoglycemic NE1 and NE2: normoglycemic supplemented with vitamin E (0.1%) and (2%), respectively; D: diabetics; DE1 and DE2: diabetics supplemented with vitamin E (0.1%) and (2%), respectively. Animals received supplementation with vitamin E for 120 days, being killed when they were 210-day-old. Proximal colon of every animal was submitted to histological processing in order to study the intestinal wall and the goblet cells and to whole mount preparations for the morphoquantitative study of the total myenteric population.
Results:
Supplementation with vitamin E significantly reduced glycemia and the values of the glycated hemoglobin and preserved the number of myenteric neurons for animals in group DE2, without effects for the intestine area, thickness of the intestinal wall and muscular tunic.
Conclusions:
It was concluded that vitamin E (2%) influenced the glycemic parameters evaluated and had a neuroprotective effect over the total myenteric population, however, morphometric characteristics of the intestinal wall were not affected.</description>
        <link>http://www.biomedcentral.com/1471-230X/9/88</link>
                <dc:creator>Luciana Roldi</dc:creator>
                <dc:creator>Renata Pereira</dc:creator>
                <dc:creator>Eleandro Tronchini</dc:creator>
                <dc:creator>Gabriela Rizo</dc:creator>
                <dc:creator>Celia Scoaris</dc:creator>
                <dc:creator>Jacqueline Zanoni</dc:creator>
                <dc:creator>Maria Natali</dc:creator>
                <dc:source>BMC Gastroenterology 2009, 9:88</dc:source>
        <dc:date>2009-11-23T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-230X-9-88</dc:identifier>
        <prism:publicationName>BMC Gastroenterology</prism:publicationName>
        <prism:issn>1471-230X</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>88</prism:startingPage>
        <prism:publicationDate>2009-11-23T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-230X/9/87">
        <title>Distribution of Helicobacter pylori virulence markers in patients with gastroduodenal diseases in Pakistan</title>
        <description>Background:
Helicobacter pylori (H. pylori) infection is known to be associated with a spectrum of gastroduodenal diseases. We studied the association of H. pylori virulence markers cytotoxin-associated gene (cagA) and vacuolating associated cytotoxin gene (vacA) alleles in patients with non ulcer dyspepsia (NUD), gastric ulcer (GU), gastric carcinoma (GC) and duodenal ulcer (DU).
Methods:
H. pylori infection established by both rapid urease test and histology were studied. The cagA and vacA allelic status was determined by polymerase chain reaction (PCR). Sequencing of vacA i1 and i2 PCR product was carried out.
Results:
Two hundred and twenty-four patients were included, 141 (63%) were males with a mean age of 45 &#177; 16, range 16-83 years. The virulence marker cagA was associated with GU in 20(63%) (p = 0.04), DU in 23(72%) (p = 0.003) and GC in 29(73%) (p = 0.001) compared to NUD in 51(42%). VacA s1am1 was associated with GU in 23(72%) (p = 0.001), DU in 17(53%) (p &lt; 0.001) and GC in 23(58%) (p = 0.003) compared to NUD in 38(32%) while vacA s1bm1 was also associated with GU in 9(28%) (p = 0.001), DU in 12(37%) (p &lt; 0.001) and GC 11(28%) (p &lt; 0.001) compared to NUD in 13(11%), respectively. The diagnoses of GU in 21(66%), DU in 16(50%), GC in 20(50%) and NUD in 50(42%) were associated with moderately active chronic inflammation. CagA in 55(45%) (p = 0.037), vacA s1am1 in 51(51%) (P &lt; 0.001), s1bm1 in 25(56%) (p = 0.002), s1am2 32(30%) (p &lt; 0.001) and s1bm2 29(69%) (p = 0.004) were also associated with moderately active chronic inflammation.
Conclusion:
CagA was negative in majority of NUD patients with H. pylori infection. However, cagA was associated with peptic ulcer and GC. VacA allele&apos;s s1am1 and s1bm1 were associated with H. pylori associated diseases and inflammation.</description>
        <link>http://www.biomedcentral.com/1471-230X/9/87</link>
                <dc:creator>Javed Yakoob</dc:creator>
                <dc:creator>Shahab Abid</dc:creator>
                <dc:creator>Zaigham Abbas</dc:creator>
                <dc:creator>Wasim Jafri</dc:creator>
                <dc:creator>Zubair Ahmad</dc:creator>
                <dc:creator>Rashida Ahmed</dc:creator>
                <dc:creator>Muhammad Islam</dc:creator>
                <dc:source>BMC Gastroenterology 2009, 9:87</dc:source>
        <dc:date>2009-11-20T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-230X-9-87</dc:identifier>
        <prism:publicationName>BMC Gastroenterology</prism:publicationName>
        <prism:issn>1471-230X</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>87</prism:startingPage>
        <prism:publicationDate>2009-11-20T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-230X/9/86">
        <title>Systematic investigation of gastrointestinal diseases in China (SILC): validation of survey methodology</title>
        <description>Background:
Symptom-based surveys suggest that the prevalence of gastrointestinal diseases is lower in China than in Western countries. The aim of this study was to validate a methodology for the epidemiological investigation of gastrointestinal symptoms and endoscopic findings in China.
Methods:
A randomized, stratified, multi-stage sampling methodology was used to select 18 000 adults aged 18-80 years from Shanghai, Beijing, Xi&apos;an, Wuhan and Guangzhou. Participants from Shanghai were invited to provide blood samples and undergo upper gastrointestinal endoscopy. All participants completed Chinese versions of the Reflux Disease Questionnaire (RDQ) and the modified Rome II questionnaire; 20% were also invited to complete the 36-item Short Form Health Survey (SF-36) and Epworth Sleepiness Scale (ESS). The psychometric properties of the questionnaires were evaluated statistically.
Results:
The study was completed by 16 091 individuals (response rate: 89.4%), with 3219 (89.4% of those invited) completing the SF-36 and ESS. All 3153 participants in Shanghai provided blood samples and 1030 (32.7%) underwent endoscopy. Cronbach&apos;s alpha coefficients were 0.89, 0.89, 0.80 and 0.91, respectively, for the RDQ, modified Rome II questionnaire, ESS and SF-36, supporting internal consistency. Factor analysis supported construct validity of all questionnaire dimensions except SF-36 psychosocial dimensions.
Conclusions:
This population-based study has great potential to characterize the relationship between gastrointestinal symptoms and endoscopic findings in China.</description>
        <link>http://www.biomedcentral.com/1471-230X/9/86</link>
                <dc:creator>Xiaoyan Yan</dc:creator>
                <dc:creator>Rui Wang</dc:creator>
                <dc:creator>Yanfang Zhao</dc:creator>
                <dc:creator>Xiuqiang Ma</dc:creator>
                <dc:creator>Jiqian Fang</dc:creator>
                <dc:creator>Hong Yan</dc:creator>
                <dc:creator>Xiaoping Kang</dc:creator>
                <dc:creator>Ping Yin</dc:creator>
                <dc:creator>Yuantao Hao</dc:creator>
                <dc:creator>Qiang Li</dc:creator>
                <dc:creator>John Dent</dc:creator>
                <dc:creator>Joseph Sung</dc:creator>
                <dc:creator>Duowu Zou</dc:creator>
                <dc:creator>Saga Johansson</dc:creator>
                <dc:creator>Katarina Halling</dc:creator>
                <dc:creator>Wenbin Liu</dc:creator>
                <dc:creator>Jia He</dc:creator>
                <dc:source>BMC Gastroenterology 2009, 9:86</dc:source>
        <dc:date>2009-11-19T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-230X-9-86</dc:identifier>
        <prism:publicationName>BMC Gastroenterology</prism:publicationName>
        <prism:issn>1471-230X</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>86</prism:startingPage>
        <prism:publicationDate>2009-11-19T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-230X/9/85">
        <title>A prospective, randomized, double-blind, placebo-controlled parallel-group dual site trial to evaluate the effects of a Bacillus coagulans-based product on functional intestinal gas symptom</title>
        <description>Background:
This randomized double blind placebo controlled dual site clinical trial compared a probiotic dietary supplement to placebo regarding effects on gastrointestinal symptoms in adults with post-prandial intestinal gas-related symptoms (abdominal pain, distention, flatulence) but no gastrointestinal (GI) diagnoses to explain the symptoms.
Methods:
Sixty-one adults were enrolled (age 36.5 &#177; 12.6 years; height 165.1 &#177; 9.2 cm; weight 75.4 &#177; 17.3 kg) and randomized to either Digestive Advantage&#8482; Gas Defense Formula - (GanedenBC30 Bacillus coagulans GBI-30, 6086): n = 30; or Placebo: n = 31. Study subjects were evaluated every two weeks over a four-week period using validated questionnaires and standard biochemical safety testing. Outcome criteria of interest included change from baseline in Gastrointestinal Symptom Rating Scale (GSRS) abdominal pain, abdominal distention, flatus, and the Severity of Dyspepsia Assessment (SODA) bloating and gas subscores over four weeks of product use.
Results:
Measured against the placebo, subjects in the probiotic group achieved significant improvements in GSRS abdominal pain subscore (p = 0.046) and the GSRS total score (p = 0.048), with a strong trend for improvement on the GSRS abdominal distension subscore (p = 0.061). A strong placebo effect was evident which could explain the lack of statistical significant differences between the groups for many of the efficacy variables.
Conclusion:
In conclusion, the Bacillus coagulans-based product was effective in improving the quality of life and reducing gastrointestinal symptoms in adults with post prandial intestinal gas-related symptoms and no GI diagnoses.Trial RegistrationClinicalTrials.gov Identifier: NCT00881322</description>
        <link>http://www.biomedcentral.com/1471-230X/9/85</link>
                <dc:creator>Douglas Kalman</dc:creator>
                <dc:creator>Howard Schwartz</dc:creator>
                <dc:creator>Patricia Alvarez</dc:creator>
                <dc:creator>Samantha Feldman</dc:creator>
                <dc:creator>John Pezzullo</dc:creator>
                <dc:creator>Diane Krieger</dc:creator>
                <dc:source>BMC Gastroenterology 2009, 9:85</dc:source>
        <dc:date>2009-11-18T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-230X-9-85</dc:identifier>
        <prism:publicationName>BMC Gastroenterology</prism:publicationName>
        <prism:issn>1471-230X</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>85</prism:startingPage>
        <prism:publicationDate>2009-11-18T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-230X/9/84">
        <title>Effects of esomeprazole treatment for gastroesophageal reflux disease on quality of life in 12- to 17-year-old adolescents: an international health outcomes study</title>
        <description>Background:
Although gastroesophageal reflux disease (GERD) is common in adolescents, the burden of GERD on health-related quality of life (HRQOL) in adolescents has not been previously evaluated. Therefore, the objective of the study was to examine the effect of GERD on HRQOL in adolescents.
Methods:
This international, 31-site, 8-week safety study randomized adolescents, aged 12 to 17 years inclusive, with GERD to receive esomeprazole 20 or 40 mg once daily. The Quality of Life in Reflux and Dyspepsia questionnaire (QOLRAD), previously validated in adults, consists of 25 questions grouped into 5 domains: emotional distress, sleep disturbance, food/drink problems, physical/social functioning, and vitality. The QOLRAD was administered at the baseline and week-8 (final) visits.
Results:
Of the 149 patients randomized, 134 completed the QOLRAD at baseline and final visits and were eligible for analysis of their HRQOL data. Baseline QOLRAD scores indicated GERD had a negative effect on the HRQOL of these adolescents, especially in the domains of vitality and emotional distress, and problems with food/drink. At the final visit, mean scores for all 5 QOLRAD domains improved significantly (P &lt; .0001); change of scores (ie, delta) for all domains met or exceeded the adult QOLRAD minimal clinically significant difference standard of 0.5 units.
Conclusion:
GERD had a negative effect on QOL in adolescents. After esomeprazole treatment, statistically and clinically significant improvements occurred in all domains of the QOLRAD for these adolescents.Trial RegistrationD9614C00098; ClinicalTrials.gov Identifier NCT00241501</description>
        <link>http://www.biomedcentral.com/1471-230X/9/84</link>
                <dc:creator>Thirumazhisai Gunasekaran</dc:creator>
                <dc:creator>Vasundhara Tolia</dc:creator>
                <dc:creator>Richard Colletti</dc:creator>
                <dc:creator>Benjamin Gold</dc:creator>
                <dc:creator>Barry Traxler</dc:creator>
                <dc:creator>Marta Illueca</dc:creator>
                <dc:creator>Joseph Crawley</dc:creator>
                <dc:source>BMC Gastroenterology 2009, 9:84</dc:source>
        <dc:date>2009-11-18T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-230X-9-84</dc:identifier>
        <prism:publicationName>BMC Gastroenterology</prism:publicationName>
        <prism:issn>1471-230X</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>84</prism:startingPage>
        <prism:publicationDate>2009-11-18T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-230X/9/83">
        <title>The effect of psychological stress on iron absorption in rats</title>
        <description>Background:
Psychological stress (PS) is recognized as an important pathogenic factor which leads to metabolism disorder in many diseases. Previous studies have shown that systemic iron homeostasis in mammalians was changed under specific stress conditions.
Methods:
In present study, we used communication box to create psychological stress model and investigated the iron apparent absorption, iron accumulation in the apical poles of villous enterocytes and protein expressions of ferroportin 1 (FPN1), ferritin, divalent metal transporter 1 (DMT1).
Results:
Our study showed that iron apparent absorption decreased and iron significantly accumulated in the apical poles of villous enterocytes in 3 d and 7 d PS groups. The expression of intestinal FPN1 in 3 d and 7 d PS groups was lower than that of control, while the change of intestinal ferritin was opposite. However, the expression of DMT1 did not change.
Conclusion:
These results demonstrate that PS can decrease iron absorption in rats, which might be related to regulation expression of iron transporters.</description>
        <link>http://www.biomedcentral.com/1471-230X/9/83</link>
                <dc:creator>Jianbo Chen</dc:creator>
                <dc:creator>Hui Shen</dc:creator>
                <dc:creator>Chengjie Chen</dc:creator>
                <dc:creator>Wanyin Wang</dc:creator>
                <dc:creator>Siyu Yu</dc:creator>
                <dc:creator>Min Zhao</dc:creator>
                <dc:creator>Min Li</dc:creator>
                <dc:source>BMC Gastroenterology 2009, 9:83</dc:source>
        <dc:date>2009-11-13T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-230X-9-83</dc:identifier>
        <prism:publicationName>BMC Gastroenterology</prism:publicationName>
        <prism:issn>1471-230X</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>83</prism:startingPage>
        <prism:publicationDate>2009-11-13T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-230X/9/82">
        <title>A comparison of diagnostic tests for lactose malabsorption - 
which one is the best?
</title>
        <description>Background:
Perceived milk intolerance is a common complaint, and tests for lactose malabsorption (LM) are unreliable. This study assesses the agreement between diagnostic tests for LM and describes the diagnostic properties of the tests.
Methods:
Patients above 18 years of age with suspected LM were included. After oral intake of 25 g lactose, a combined test with measurement of serum glucose (s-glucose) and hydrogen (H2) and methane (CH4) in expired air was performed and symptoms were recorded. In patients with discrepancies between the results, the combined test was repeated and a gene test for lactose non-persistence was added. The diagnosis of LM was based on an evaluation of all tests. The following tests were compared: Increase in H2, CH4, H2+CH4 and H2+CH4x2 in expired air, increase in s-glucose, and symptoms. The agreement was calculated and the diagnostic properties described.
Results:
Sixty patients were included, seven (12%) had LM. The agreement (kappa-values) between the methods varied from 0.25 to 0.91. The best test was the lactose breath test with measurement of the increase in H2 + CH4x2 in expired air. With a cut-off level &lt; 18 ppm, the area under the ROC-curve was 0.967 and sensitivity was 100%. This shows that measurement of CH4 in addition to H2 improves the diagnostic properties of the breath test.
Conclusion:
The agreement between commonly used methods for the diagnosis of LM was unsatisfactory. A lactose breath test with measurement of H2 + CH4x2 in expired air had the best diagnostic properties.</description>
        <link>http://www.biomedcentral.com/1471-230X/9/82</link>
                <dc:creator>Oistein Hovde</dc:creator>
                <dc:creator>Per Farup</dc:creator>
                <dc:source>BMC Gastroenterology 2009, 9:82</dc:source>
        <dc:date>2009-10-31T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-230X-9-82</dc:identifier>
        <prism:publicationName>BMC Gastroenterology</prism:publicationName>
        <prism:issn>1471-230X</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>82</prism:startingPage>
        <prism:publicationDate>2009-10-31T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
        <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks" />
    </cc:License>
</rdf:RDF>
